137 related articles for article (PubMed ID: 30442938)
1. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.
Veenstra VL; Damhofer H; Waasdorp C; van Rijssen LB; van de Vijver MJ; Dijk F; Wilmink HW; Besselink MG; Busch OR; Chang DK; Bailey PJ; Biankin AV; Kocher HM; Medema JP; Li JS; Jiang R; Pierce DW; van Laarhoven HWM; Bijlsma MF
Oncogenesis; 2018 Nov; 7(11):87. PubMed ID: 30442938
[TBL] [Abstract][Full Text] [Related]
2. Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer.
Strijker M; van der Sijde F; Suker M; Boermeester MA; Bonsing BA; Bruno MJ; Busch OR; Doukas M; van Eijck CH; Gerritsen A; Groot Koerkamp B; Haj Mohammad N; van Hilst J; de Hingh IH; van Hooft JE; Luyer MD; Quintus Molenaar I; Verheij J; Waasdorp C; Wilmink JW; Besselink MG; van Laarhoven HW; Bijlsma MF;
HPB (Oxford); 2021 Dec; 23(12):1886-1896. PubMed ID: 34103247
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant nab-paclitaxel plus gemcitabine
Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
[TBL] [Abstract][Full Text] [Related]
4.
Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
[TBL] [Abstract][Full Text] [Related]
5. Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer.
Ten Hoorn S; Waasdorp C; van Oijen MGH; Damhofer H; Trinh A; Zhao L; Smits LJH; Bootsma S; van Pelt GW; Mesker WE; Mol L; Goey KKH; Koopman M; Medema JP; Tuynman JB; Zlobec I; Punt CJA; Vermeulen L; Bijlsma MF
BMC Cancer; 2022 Apr; 22(1):394. PubMed ID: 35413826
[TBL] [Abstract][Full Text] [Related]
6. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma.
Yu KH; Ricigliano M; McCarthy B; Chou JF; Capanu M; Cooper B; Bartlett A; Covington C; Lowery MA; O'Reilly EM
Cancers (Basel); 2018 Nov; 10(12):. PubMed ID: 30477242
[TBL] [Abstract][Full Text] [Related]
8. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
[TBL] [Abstract][Full Text] [Related]
9. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
[TBL] [Abstract][Full Text] [Related]
10. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
11. Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study).
Schokker S; van der Woude SO; van Kleef JJ; van Zoen DJ; van Oijen MGH; Mearadji B; Beenen LFM; Stroes CI; Waasdorp C; Jibodh RA; Creemers A; Meijer SL; Hooijer GKJ; Punt CJA; Bijlsma MF; van Laarhoven HWM
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31207904
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
Lemstrova R; Melichar B; Mohelnikova-Duchonova B
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1101-1111. PubMed ID: 27250969
[TBL] [Abstract][Full Text] [Related]
13. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials.
Ormanns S; Haas M; Baechmann S; Altendorf-Hofmann A; Remold A; Quietzsch D; Clemens MR; Bentz M; Geissler M; Lambertz H; Kruger S; Kirchner T; Heinemann V; Boeck S
Br J Cancer; 2016 Dec; 115(12):1520-1529. PubMed ID: 27802454
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and resource utilization of
Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
[TBL] [Abstract][Full Text] [Related]
15. The
Palacio S; Hosein PJ; Reis I; Akunyili II; Ernani V; Pollack T; Macintyre J; Restrepo MH; Merchan JR; Rocha Lima CM
J Gastrointest Oncol; 2018 Feb; 9(1):135-139. PubMed ID: 29564179
[TBL] [Abstract][Full Text] [Related]
16. Thymic stromal lymphopoietin in human pancreatic ductal adenocarcinoma: expression and prognostic significance.
Vizio B; Boita M; Cristiano C; Mazibrada J; Bosco O; Novarino A; Prati A; Sciascia S; Rolla G; Ciuffreda L; Montrucchio G; Bellone G
Oncotarget; 2018 Aug; 9(67):32795-32809. PubMed ID: 30214685
[TBL] [Abstract][Full Text] [Related]
17. New Advances in the Treatment of Metastatic Pancreatic Cancer.
Schober M; Javed MA; Beyer G; Le N; Vinci A; Sund M; Neesse A; Krug S
Digestion; 2015; 92(3):175-84. PubMed ID: 26372949
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients.
Xiao Y; Chen W; Xie Z; Shao Z; Xie H; Qin G; Zhao N
BMC Cancer; 2017 Jan; 17(1):25. PubMed ID: 28056913
[TBL] [Abstract][Full Text] [Related]
19. Stromal SPOCK1 supports invasive pancreatic cancer growth.
Veenstra VL; Damhofer H; Waasdorp C; Steins A; Kocher HM; Medema JP; van Laarhoven HW; Bijlsma MF
Mol Oncol; 2017 Aug; 11(8):1050-1064. PubMed ID: 28486750
[TBL] [Abstract][Full Text] [Related]
20. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report.
Okura R; Takano S; Yokota T; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Miyazaki M; Ohtsuka M
Mol Clin Oncol; 2018 Oct; 9(4):389-393. PubMed ID: 30214727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
